The Food and Drug Administration declined to approve MDMA-assisted therapy for PTSD, citing insufficient data. This decision dashed hopes for new treatments and further research is requested by the FDA.
Approval would have marked a significant milestone in the study of psychedelic compounds. Experts voted against the company's application, stating the treatment's effectiveness was not proven, and risks outweighed benefits.
Collection
[
|
...
]